These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 8695345)

  • 41. Topoisomerase-I inhibitors in the management of colon cancer.
    Willson JK
    Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519
    [No Abstract]   [Full Text] [Related]  

  • 42. Camptothecin and its analogs. An overview of their potential in cancer therapeutics.
    Muggia FM; Dimery I; Arbuck SG
    Ann N Y Acad Sci; 1996 Dec; 803():213-23. PubMed ID: 8993515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Irinotecan for the treatment of cervical cancer.
    Verschraegen CF
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):32-4. PubMed ID: 12109804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A risk-benefit assessment of irinotecan in solid tumours.
    Siu LL; Rowinsky EK
    Drug Saf; 1998 Jun; 18(6):395-417. PubMed ID: 9638386
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Camptothecins: new enthusiasm for an old drug.
    Rowe PM
    Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402
    [No Abstract]   [Full Text] [Related]  

  • 47. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Irinotecan in colorectal cancer].
    Pozzo C; Cassano A; Barone C
    Tumori; 2001; 87(1 Suppl 1):S49-50. PubMed ID: 11300023
    [No Abstract]   [Full Text] [Related]  

  • 49. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
    Adjei AA; Argiris A; Murren JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
    Wethington SL; Wright JD; Herzog TJ
    Expert Rev Anticancer Ther; 2008 May; 8(5):819-31. PubMed ID: 18471053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
    Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA approves irinotecan as first-line therapy for colorectal cancer.
    Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
    [No Abstract]   [Full Text] [Related]  

  • 54. Irinotecan and radiation in combined-modality therapy for solid tumors.
    Choy H; MacRae R
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):22-8. PubMed ID: 11497228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Irinotecan in epithelial ovarian cancer.
    Gershenson DM
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):29-31. PubMed ID: 12109803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
    Isobe T; Ishikawa N; Oguri T
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1267-78. PubMed ID: 10945026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
    Jonsson E; Dhar S; Jonsson B; Nygren P; Graf W; Larsson R
    Eur J Cancer; 2000 Oct; 36(16):2120-7. PubMed ID: 11044651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Boige V; Raymond E; Armand JP
    Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical pharmacology of camptothecins.
    Iyer L; Ratain MJ
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S31-43. PubMed ID: 9750027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.